The AIFM1 (Apoptosis-Inducing Factor Mitochondrial 1) antibody targets a protein encoded by the *AIFM1* gene, which plays a critical role in mitochondrial energy metabolism and programmed cell death. AIFM1 is a flavoprotein located in the mitochondrial intermembrane space, functioning primarily as an NADH oxidase essential for oxidative phosphorylation. Beyond its metabolic role, AIFM1 is a key mediator of caspase-independent apoptosis. Upon cellular stress, it translocates to the nucleus, triggering chromatin condensation and DNA fragmentation. Mutations in *AIFM1* are linked to severe human disorders, including X-linked Charcot-Marie-Tooth disease, mitochondrial encephalopathy, and neurodevelopmental defects, highlighting its importance in neuronal and muscular health.
AIFM1 antibodies are widely used in research to study protein expression, localization, and function via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They help investigate AIFM1’s dual roles in cell survival and death, particularly in neurodegenerative diseases, cancer, and ischemia-reperfusion injury. Commercially available antibodies are typically raised in rabbits or mice, targeting specific epitopes across AIFM1’s functional domains. Validation includes knockout controls to ensure specificity. Recent studies also explore AIFM1’s involvement in redox signaling and inflammatory responses, expanding its therapeutic relevance. Thus, AIFM1 antibodies serve as vital tools for unraveling mitochondrial biology and disease mechanisms.